RET
RET is a bipolar receptor tyrosine kinase that dictates the development of the nervous and renal systems. Its signaling spectrum is uniquely broad: while its loss prevents the formation of the colons nervous system (Hirschsprung disease), its "awakening" via mutation or fusion drives aggressive endocrine and lung cancers, making it a masterpiece of precision genetic targeting.
Key Takeaways
- •RET is a "bipolar" gene: too little signaling causes birth defects, while too much causes cancer.
- •It is the primary driver of Medullary Thyroid Cancer through specific inherited mutations (MEN2).
- •RET mutations in lung cancer often affect younger non-smokers and have excellent response to targeted therapy.
- •In children, RET loss causes Hirschsprung disease, where the colon lacks the nerves needed for movement.
- •Precision RET inhibitors like Selpercatinib are designed to turn off the "short circuit" in cancer with high accuracy.
Basic Information
- Gene Symbol
- RET
- Full Name
- Ret Proto-Oncogene
- Also Known As
- CDHF12HSCR1MEN2AMEN2BPTC
- Location
- 10q11.21
- Protein Type
- Receptor Tyrosine Kinase
- Protein Family
- Cadherin superfamily
Related Isoforms
The major functional receptor involved in neural and renal development.
Key SNPs
Common polymorphism that may act as a modifier of RET-related disease phenotypes.
Associated with altered RET expression and risk for Hirschsprung disease.
Classic MEN2A hotspot mutation; leads to ligand-independent dimerization.
Defining mutation for MEN2B; alters substrate specificity and confers aggressive behavior.
Gatekeeper mutation in the kinase domain; can confer resistance to early multi-kinase inhibitors.
Strongly associated with Hirschsprung disease risk; reduces RET enhancer activity.
Overview
The RET proto-oncogene encodes a receptor tyrosine kinase that is indispensable for normal human development. It acts as the signal-transducing component of a multi-protein complex that responds to the Glial cell line-derived Neurotrophic Factor (GDNF) family of ligands. This signaling is critical for the migration of neural crest cells that form the enteric nervous system and for the branching morphogenesis of the kidney during fetal development.
In clinical genetics, RET is famous for its "bipolar" pathogenic spectrum. On one hand, loss-of-function mutations result in the failure of the enteric nervous system to develop, causing Hirschsprung disease. On the other hand, gain-of-function mutations (either as chromosomal fusions or point mutations) lead to constitutive signaling and the development of multiple cancer types, including medullary thyroid carcinoma and NSCLC.
Conceptual Model
A simplified mental model for the pathway:
Precise tuning of RET activity is required: too little prevents organ development, while too much causes cancer.
Core Health Impacts
- • Enteric Wiring: Essential for the migration and survival of neurons that control the gut.
- • Kidney Branching: Master regulator of ureteric branching during the formation of the kidney.
- • Endocrine Growth: Defining driver in medullary and papillary thyroid cancers.
- • Germ Cell Survival: Maintains spermatogonial stem cells, essential for male reproductive health.
- • Neuroprotection: Acts as a survival factor for dopaminergic neurons in the brain.
Protein Domains
Cadherin-Like
Extracellular region that mediates calcium-dependent positioning of the receptor.
Cysteine-Rich
Domain near the membrane; mutations here (MEN2A) cause illegal disulfide bonding.
Kinase Domain
The internal engine; hotspot for mutations (MEN2B) that change substrate preference.
Upstream Regulators
GDNF Family Ligands Activator
Includes GDNF, Neurturin, Persephin, and Artemin; requires GFRalpha co-receptors for binding.
GFRalpha1-4 Co-receptors Activator
GPI-anchored proteins that capture ligands and present them to the RET receptor.
Gene Fusion (KIF5B-RET) Activator
Chromosomal rearrangement common in NSCLC; creates a constitutively active fusion protein.
CCDC6-RET (PTC1) Activator
Fusion found in papillary thyroid cancer that drives oncogenic signaling.
Src Kinase Activator
Can phosphorylate RET and promote its activation and downstream survival cascades.
Soluble GFRalpha1 Activator
Can act in "trans" to activate RET in cells that do not express the co-receptor themselves.
Downstream Targets
MAPK / ERK Pathway Activates
Primary driver of cell proliferation and differentiation downstream of RET.
PI3K / AKT Pathway Activates
Essential for cell survival and resistance to apoptosis in RET-driven cancers.
JAK / STAT3 Activates
Mediates survival signals and contributes to the aggressive phenotype of MTC.
PLC-gamma Activates
Regulates calcium signaling and influences enteric nervous system development.
Rac / Rho GTPases Activates
Control cell motility and migration; critical for the development of the enteric nervous system.
Cyclin D1 Activates
Transcriptionally regulated by RET; promotes cell cycle progression through G1/S.
Role in Aging
RET signaling is primarily associated with development and oncology, but its role in neuroprotection suggests it may be a factor in age-related neurological health.
Neuroprotection
GDNF/RET signaling is a major survival factor for dopaminergic neurons; its decline is linked to Parkinson disease.
GI Motility
Age-related changes in the enteric nervous system may involve altered RET signaling, contributing to constipation.
Kidney Resilience
Because RET is vital for kidney architecture, its baseline function may influence nephron reserve in old age.
Stem Cell Support
In the testis and other niches, RET supports the survival of long-lived stem cell populations.
Endocrine Aging
Alterations in thyroid C-cell and parathyroid function over time may intersect with RET pathway tone.
Somatic Mutations
Age-related accumulation of mutations in thyroid or lung tissues can lead to the awakening of RET as an oncogene.
Disorders & Diseases
Medullary Thyroid Cancer
RET is the dominant driver; point mutations (MEN2A/B) lead to hereditary and sporadic forms.
Lung Cancer (RET+)
Driven by fusions (e.g., KIF5B-RET). Occurs in 1-2% of NSCLC, often in non-smokers.
Hirschsprung Disease
Congenital lack of nerves in the colon caused by loss-of-function mutations or low RET expression.
Pheochromocytoma
Adrenal gland tumors that arise in 50% of patients with MEN2A/B syndromes.
Papillary Thyroid Cancer
Fusions like CCDC6-RET (PTC1) are common drivers in this most frequent form of thyroid cancer.
Interventions
Supplements
Support thyroid and endocrine health, although no specific supplement targets RET.
Studied for broad anti-inflammatory effects that may complement oncology treatments.
Important for calcium homeostasis, particularly in patients with MEN2A parathyroid involvement.
Essential for general thyroid function, though medullary cancer is independent of iodine.
Lifestyle
Essential for families with MEN2 history to manage risk and timing of preventative surgery.
Regular monitoring of calcitonin and CEA for early detection of medullary thyroid cancer.
Thyroidectomy is the standard of care for children carrying high-risk MEN2 germline mutations.
Supports overall metabolic health and reduces insulin-driven growth signals.
Medicines
Highly selective RET inhibitor with excellent brain penetration; a breakthrough for RET cancers.
Selective inhibitor targeting RET fusions and mutations; effective against gatekeeper variants.
Multi-kinase inhibitor (MET/VEGFR/RET) approved for progressive medullary thyroid cancer.
Multi-kinase inhibitor used in the treatment of advanced medullary thyroid cancer.
Lab Tests & Biomarkers
Genetic Status
Crucial for identifying MEN2 risk and timing prophylactic thyroidectomy.
Detection of KIF5B-RET or other partners in lung or thyroid biopsy samples.
Targeted NGS for M918T or V804 gatekeeper resistance mutations.
Tumor Markers
Primary tumor marker for medullary thyroid cancer; reflects RET-driven activity.
Secondary marker for monitoring thyroid cancer progression and response.
Screening tool for pheochromocytoma in MEN2 patients.
Hormonal Interactions
Calcitonin Clinical Marker
Serum levels are a direct proxy for RET-driven thyroid C-cell burden.
PTH Syndromic Marker
Parathyroid hormone; monitored in MEN2A patients to detect hyperparathyroidism.
Insulin Pathway Crosstalk
Synergizes with RET signaling to drive growth and survival in endocrine tumors.
Thyroid Hormones Metabolic Context
T3/T4 levels reflect general thyroid status but are distinct from RET-driven MTC.
Deep Dive
Network Diagrams
RET Signaling Assembly
RET Pathogenic Spectrum
The Two Faces of RET: Too Little vs. Too Much
RET is one of the best examples in genetics of how the type of mutation determines the disease. It operates like a dimmer switch for cellular signaling.
- ** Hirschsprung Disease (Silent Circuit):** If the RET gene is lost or weakened, the “nerves of the gut” never migrate to the end of the colon during development. This results in a child who cannot pass stool because the end of the colon is permanently paralyzed. This is a Loss-of-Function disorder.
- MEN2 Syndromes (Short Circuit): If the RET gene is mutated to be overactive, it sends a non-stop signal for growth. In MEN2A, the receptors are physically “welded” together by a cysteine mutation. In MEN2B, the internal kinase engine is modified to run faster. These are Gain-of-Function disorders leading to aggressive thyroid cancer.
The GDNF Connection and Neuroprotection
While RET is a villain in cancer, it is a hero in the brain. Its primary ligand is GDNF (Glial cell line-derived Neurotrophic Factor).
- Dopamine Survival: In the adult brain, RET signaling is a major survival factor for the neurons that produce dopamine.
- Parkinson Research: Scientists have long investigated ways to deliver GDNF directly into the brain to activate RET and “rescue” the dying neurons in Parkinson patients. While clinical trials have been difficult due to delivery challenges, the RET pathway remains a holy grail for neuroregeneration.
Precision Targeting: Pushing the Solvent Front
The evolution of RET inhibitors reflects the extreme precision of modern medicine. Early drugs were “dirty”—they hit RET but also hit many other kinases, leading to high toxicity.
Modern “selective” RET inhibitors like Selpercatinib were engineered to fit perfectly into the RET kinase pocket. They are so precise that they can even overcome “gatekeeper” mutations that the tumor uses to block the drug. These drugs represent the pinnacle of “oncogene addiction” therapy, where turning off one specific gene can lead to complete tumor regression with minimal side effects for the patient.
Interpreting RET Status
IHC vs FISH. High-sensitivity IHC is now widely accepted as a standard test for RET expression in lung tissue.
Calcitonin Speed. In medullary cancer, how fast calcitonin levels are rising is more important than the absolute number.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The original discovery of RET as a transforming gene through chromosomal rearrangement.
Established the genetic basis for MEN2A, linking RET mutations to inherited cancer syndromes.
Pivotal trial leading to the approval of highly selective RET inhibitors.
Clinical trial demonstrating the efficacy of pralsetinib in RET fusion-positive NSCLC.
Key trial establishing the role of early multi-kinase inhibitors in MTC.
Comprehensive review of RET signaling mechanisms in normal development and cancer.